1-hydroxymethylmidazolam has been researched along with quinidine in 3 studies
| Studies (1-hydroxymethylmidazolam) | Trials (1-hydroxymethylmidazolam) | Recent Studies (post-2010) (1-hydroxymethylmidazolam) | Studies (quinidine) | Trials (quinidine) | Recent Studies (post-2010) (quinidine) |
|---|---|---|---|---|---|
| 163 | 46 | 49 | 6,608 | 387 | 594 |
| Protein | Taxonomy | 1-hydroxymethylmidazolam (IC50) | quinidine (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 6.4 | |
| Cholinesterase | Homo sapiens (human) | 1.23 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 3.32 | |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | 2.8 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.3532 | |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | 7.3 | |
| Cholinesterase | Equus caballus (horse) | 7.37 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 6.4 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.7882 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 6.4 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 6.4 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 6.9 | |
| Potassium voltage-gated channel subfamily D member 2 | Rattus norvegicus (Norway rat) | 2.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Follath, F; Freiburghaus, AU; Ha, HR; Leuenberger, PM | 1 |
| Bayliss, MK; Eddershaw, PJ; Herriott, D; Manchee, GR; Park, GR; Ranshaw, LE; Tarbit, MH | 1 |
| Baba, K; Hamahata, Y; Hayashi, M; Iwanaga, K; Kakemi, M; Miyazaki, M; Shibano, M; Taniguchi, M | 1 |
3 other study(ies) available for 1-hydroxymethylmidazolam and quinidine
| Article | Year |
|---|---|
In vitro inhibition of midazolam and quinidine metabolism by flavonoids.
Topics: Anti-Arrhythmia Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Flavonoids; Humans; Kinetics; Midazolam; Mixed Function Oxygenases; Quinidine | 1995 |
The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
Topics: Adrenergic beta-Agonists; Albuterol; Biomarkers; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disulfiram; Humans; Isoenzymes; Ketoconazole; Microsomes, Liver; Midazolam; Molecular Structure; Oxidation-Reduction; Quinidine; Recombinant Proteins; Salmeterol Xinafoate; Sulfaphenazole; Theophylline | 1996 |
Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
Topics: Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Furocoumarins; Humans; Medicine, Kampo; Midazolam; Quinidine | 2010 |